,  том 2 ,  издание 9 ,  страницы 1900042

Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

Тип публикации: Journal Article
Дата публикации: 2019-06-28
SCImago Q2
WOS Q2
БС1
SJR: 0.651
CiteScore: 4.9
Impact factor: 3.2
ISSN: 23663987
Medicine (miscellaneous)
Pharmacology
Pharmaceutical Science
Pharmacology (medical)
Genetics (clinical)
Biochemistry (medical)
Краткое описание

The organometallic ruthenium(II) [Ru(arene)Cl2PTA] PTA ‐ 1,3,5‐triaza‐7‐phosphaadamantane compound, RAPTA‐C, represents an innovative anti‐cancer therapeutic and a better‐tolerated alternative to platinum (Pt)‐based chemotherapeutic drugs in the treatment of cancer. RAPTA‐C exhibits anti‐metastatic, anti‐angiogenic, and anti‐tumoral activities through protein and histone–deoxyribonucleic acid alterations. In comparison to other ruthenium‐based drugs, which have been recently evaluated in clinical trials, RAPTA‐C is strikingly competitive, especially when administered in combination with other targeted drugs. In this review, the uniqueness of RAPTA‐C as an anti‐cancer chemotherapeutic compared to metal‐based drugs under clinical evaluation and those approved by the Food and Drug Administration is emphasized; specifically, comparing the application of RAPTA‐C to platinum‐based drugs, for example, cisplatin and oxaliplatin, as well as to prominent ruthenium‐based compounds, such as NAMI‐A imidazolium‐trans‐tetrachloro(dimethylsulfoxide) imidazoleruthenium(III) and trans‐[tetrachlorobis (1Hindazole) ruthenate(III)] (KP1019)/(N)KP1339 (N)KP1339 ‐ sodium. Additionally, the possible correlation between RAPTA‐C and immune response modulation, as well as potential applications of RAPTA‐C in combination with immune therapeutic regimens, is highlighted.

Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

2
4
6
8
10
Inorganic Chemistry
10 публикаций, 11.49%
Coordination Chemistry Reviews
8 публикаций, 9.2%
Journal of Medicinal Chemistry
6 публикаций, 6.9%
Dalton Transactions
5 публикаций, 5.75%
Applied Organometallic Chemistry
4 публикации, 4.6%
Pharmaceuticals
3 публикации, 3.45%
Molecules
3 публикации, 3.45%
Inorganica Chimica Acta
3 публикации, 3.45%
Chemistry - A European Journal
3 публикации, 3.45%
ChemMedChem
3 публикации, 3.45%
Pharmaceutics
2 публикации, 2.3%
European Journal of Medicinal Chemistry
2 публикации, 2.3%
Polyhedron
2 публикации, 2.3%
Journal of Materials Chemistry B
2 публикации, 2.3%
New Journal of Chemistry
2 публикации, 2.3%
Journal of Inorganic Biochemistry
2 публикации, 2.3%
Angewandte Chemie - International Edition
1 публикация, 1.15%
Journal of Physical Chemistry C
1 публикация, 1.15%
Molecular Pharmaceutics
1 публикация, 1.15%
Cancers
1 публикация, 1.15%
Journal of Biological Inorganic Chemistry
1 публикация, 1.15%
Biomaterials Advances
1 публикация, 1.15%
Current Opinion in Chemical Biology
1 публикация, 1.15%
Chemico-Biological Interactions
1 публикация, 1.15%
ChemBioChem
1 публикация, 1.15%
Chemical Record
1 публикация, 1.15%
Angewandte Chemie
1 публикация, 1.15%
Photochemistry and Photobiology
1 публикация, 1.15%
Chemistry and Biodiversity
1 публикация, 1.15%
ACS Omega
1 публикация, 1.15%
2
4
6
8
10

Издатели

5
10
15
20
25
Elsevier
23 публикации, 26.44%
American Chemical Society (ACS)
21 публикация, 24.14%
Wiley
17 публикаций, 19.54%
Royal Society of Chemistry (RSC)
12 публикаций, 13.79%
MDPI
10 публикаций, 11.49%
Springer Nature
1 публикация, 1.15%
Taylor & Francis
1 публикация, 1.15%
Hindawi Limited
1 публикация, 1.15%
Scientific Publishers
1 публикация, 1.15%
5
10
15
20
25
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
87
Поделиться
Цитировать
ГОСТ |
Цитировать
Rausch M. et al. Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies // Advanced Therapeutics. 2019. Vol. 2. No. 9. p. 1900042.
ГОСТ со всеми авторами (до 50) Скопировать
Rausch M., Dyson P. J., Nowak-Sliwinska P. Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies // Advanced Therapeutics. 2019. Vol. 2. No. 9. p. 1900042.
RIS |
Цитировать
TY - JOUR
DO - 10.1002/adtp.201900042
UR - https://onlinelibrary.wiley.com/doi/10.1002/adtp.201900042
TI - Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies
T2 - Advanced Therapeutics
AU - Rausch, Magdalena
AU - Dyson, Paul J.
AU - Nowak-Sliwinska, Patrycja
PY - 2019
DA - 2019/06/28
PB - Wiley
SP - 1900042
IS - 9
VL - 2
SN - 2366-3987
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2019_Rausch,
author = {Magdalena Rausch and Paul J. Dyson and Patrycja Nowak-Sliwinska},
title = {Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies},
journal = {Advanced Therapeutics},
year = {2019},
volume = {2},
publisher = {Wiley},
month = {jun},
url = {https://onlinelibrary.wiley.com/doi/10.1002/adtp.201900042},
number = {9},
pages = {1900042},
doi = {10.1002/adtp.201900042}
}
MLA
Цитировать
Rausch, Magdalena, et al. “Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies.” Advanced Therapeutics, vol. 2, no. 9, Jun. 2019, p. 1900042. https://onlinelibrary.wiley.com/doi/10.1002/adtp.201900042.
Ошибка в публикации?